The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
ApexOnco Front Page
Recent articles
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
$650m buys the group rights to RemeGen’s RC148.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
JP Morgan approaches.
